Equities Analysts Offer Predictions for Neogen Q3 Earnings

Neogen Corporation (NASDAQ:NEOGFree Report) – Analysts at Zacks Research reduced their Q3 2026 earnings estimates for shares of Neogen in a research report issued to clients and investors on Friday, March 6th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.02 per share for the quarter, down from their previous estimate of $0.04. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s FY2026 earnings at $0.20 EPS, Q1 2027 earnings at $0.05 EPS and Q2 2027 earnings at $0.07 EPS.

Neogen (NASDAQ:NEOGGet Free Report) last announced its earnings results on Thursday, January 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.03. Neogen had a negative net margin of 68.47% and a positive return on equity of 2.14%. The business had revenue of $224.69 million during the quarter, compared to analysts’ expectations of $208.50 million. During the same quarter last year, the company posted $0.11 EPS. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis.

Several other analysts have also weighed in on the stock. CJS Securities upgraded shares of Neogen from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, December 10th. William Blair reissued a “market perform” rating on shares of Neogen in a report on Monday, March 2nd. Guggenheim restated a “buy” rating and set a $12.00 price target (up from $8.00) on shares of Neogen in a research report on Friday, January 9th. Piper Sandler reaffirmed a “neutral” rating and set a $10.00 price target (up from $6.50) on shares of Neogen in a report on Monday, January 12th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Neogen in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.67.

View Our Latest Research Report on Neogen

Neogen Price Performance

NASDAQ:NEOG opened at $9.70 on Monday. The company has a quick ratio of 2.80, a current ratio of 3.91 and a debt-to-equity ratio of 0.38. The firm has a market cap of $2.11 billion, a PE ratio of -3.50 and a beta of 1.95. Neogen has a 12 month low of $3.87 and a 12 month high of $11.43. The company’s 50-day moving average price is $9.87 and its two-hundred day moving average price is $7.40.

Hedge Funds Weigh In On Neogen

A number of large investors have recently modified their holdings of the stock. UMB Bank n.a. increased its holdings in shares of Neogen by 238.2% in the fourth quarter. UMB Bank n.a. now owns 6,422 shares of the company’s stock valued at $45,000 after purchasing an additional 4,523 shares in the last quarter. Savant Capital LLC acquired a new position in Neogen during the 2nd quarter worth $50,000. Hantz Financial Services Inc. boosted its position in Neogen by 816.9% in the 4th quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company’s stock valued at $53,000 after buying an additional 6,764 shares during the last quarter. Cresset Asset Management LLC bought a new position in Neogen in the 2nd quarter valued at $53,000. Finally, Evergreen Capital Management LLC acquired a new stake in shares of Neogen in the 2nd quarter valued at $56,000. 96.73% of the stock is currently owned by institutional investors and hedge funds.

Neogen Company Profile

(Get Free Report)

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.

Featured Stories

Earnings History and Estimates for Neogen (NASDAQ:NEOG)

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.